CAR T Cell Therapy
9
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia
Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products
CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma
Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond
DALY II Japan/MB-CART2019.1 for DLBCL
Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy
MB-CART2019.1 in Refractory Multiple Sclerosis
Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE